IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

MÜLLER et al.

Serial No. **09/912,414**

Filed: **July 26, 2001**

Atty. Ref.: **620-151**

Group:

Examiner:

For: **TRANSCRIPTION FACTOR E2F DNA-BINDING DOMAIN INHIBITOR PEPTIDES AND THEIR USE**

* * * * * * * * * * *

November 19, 2001

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

STATEMENT

The attached paper and computer-readable copies of the Sequence Listing are the same. No new matter has been added.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____

B. J. Sadoff
Reg. No. **36,663**

BJS:eaw
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

SEQUENCE LISTING

<110> Müller, Rolf
Kontermann, Roland E
Montigiani, Silvia

<120> Transcription factor E2F DNA-binding domain inhibitor peptides and their use

<130> 620-151

<140> US 09/912,414
<141> 2001-07-26

<150> PCT/GB00/00227
<151> 2000-01-26

<150> GB 9901710.5
<151> 1999-01-26

<160> 40

<170> PatentIn Ver. 2.1

<210> 1
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 1
Phe Trp Leu Arg Phe Thr
1 5

<210> 2
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 2
Trp Val Arg Trp His Phe
1 5

<210> 3
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 3
Trp His Phe Ile Phe Trp
1 5

<210> 4
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 4
Ile Trp Leu Ser Gly Leu Ser Arg Gly Val Trp Val Ser Phe Pro
1 5 10 15

<210> 5
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 5
Gly Ser Arg Ile Leu Thr Phe Arg Ser Gly Ser Trp Tyr Ala Ser
1 5 10 15

<210> 6
<211> 16
<212> PRT
<213> Drosophila melanogaster

<400> 6
Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys
1 5 10 15

<210> 7
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<221> SITE
<222> (1)
<223> In Claims 1 & 2, Xaa is an amino terminal or a sequence of from 1 to 4 amino acids

<220>
<221> SITE
<222> (1)
<223> In Claim 3, Xaa is an amino terminal or a sequence of from 1 to 4 amino acids each of which are selected from Gly, Ala, Ile, Leu, Val, Ser, Thr, Lys, or Arg

<220>
<221> SITE
<222> (2)
<223> In Claim 1, Xaa is an aromatic amino acid

<220>
<221> SITE
<222> (2)
<223> In Claims 2 and 3, Xaa is Phe or Trp

<220>
<221> SITE
<222> (3)
<223> In Claims 1 & 2, Xaa is from two to four amino acids

<220>
<221> SITE
<222> (3)
<223> In Claim 3, Xaa is from two to four amino acids each of which are selected from Gly, Ala, Ile, Leu, Val, Ser, Thr, Lys, Arg, His or Phe

<220>
<221> SITE
<222> (4)
<223> In Claim 1, Xaa is an aromatic amino acid

<220>
<221> SITE
<222> (4)
<223> In Claim 2, Xaa is Phe or Trp

<220>
<221> SITE
<222> (4)
<223> In Claim 3, Xaa is Trp

<220>
<221> SITE
<222> (5)
<223> In Claims 1 & 2, Xaa is a carboxy terminal or a sequence of from one to four amino acids

<220>
<221> SITE
<222> (5)
<223> In Claim 3, Xaa is a carboxy terminal or a sequence of from one to four amino acids each of which are selected from Gly, Ala, Ile, Leu, Val, Ser, Thr, Lys, Arg, His, Phe or Tyr

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 7
Xaa Xaa Xaa Xaa Xaa
1 5

<210> 8
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> SITE
<222> (2)..(3), (5)..(6)
<223> Each Xaa is independently any amino acid

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 8
Trp Xaa Xaa Trp Xaa Xaa
1 5

<210> 9
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> SITE
<222> (2)..(3), (5)
<223> Each Xaa is independently any amino acid selected from Gly, Ala, Ile, Leu, Val, Ser, Thr, Lys, Arg, His, or Phe

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 9
Trp Xaa Xaa Trp Xaa Phe
1 5

<210> 10
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<221> SITE
<222> (2)..(3), (5), (7)..(8)
<223> Each Xaa is independently any amino acid selected from Gly, Ala, Ile, Leu, Val, Ser, Thr, Lys, Arg, His, or Phe

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 10
Trp Xaa Xaa Trp Xaa Phe Xaa Xaa Trp
1 5

<210> 11
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<221> SITE
<222> (2)..(3)
<223> Each Xaa is independently any amino acid selected from Gly, Ala, Ile, Leu, Val, Ser, Thr, or Arg

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 11
Trp Xaa Xaa Trp His Phe
1 5

<210> 12
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> SITE
<222> (1)..(2), (4)..(7)
<223> Each Xaa is independently any amino acid

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 12
Xaa Xaa Phe Xaa Xaa Xaa Xaa Trp
1 5

<210> 13
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> SITE
<222> (1)..(2), (4)..(7)
<223> Each Xaa is independently any amino acid selected from Gly, Ala, Ile, Leu, Val, Ser, Thr, Lys, Arg, His, Phe, or Tyr

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 13
Xaa Xaa Phe Xaa Xaa Xaa Xaa Trp
1 5

<210> 14
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> SITE
<222> (1)..(2)
<223> Each Xaa is independently any amino acid selected from Gly, Ala, Ile, Leu, Val, Ser, Thr, Lys, Arg, His, Phe, or Tyr

<220>
<221> SITE
<222> (5)
<223> Xaa is independently any amino acid selected from Gly, Ala, Ile, Leu, Val, Ser, Thr, Lys, Arg, His, Phe, or Tyr

<220>
<221> SITE
<222> (6)
<223> Xaa is independently any amino acid selected from Gly, Ala, Ile, Leu, Val, Ser, Thr, Lys, Arg, His, Phe, or Tyr

<220>
<221> SITE
<222> (7)
<223> Xaa is independently any amino acid selected from Gly, Ala, Ile, Leu, Val, Ser, Thr, Lys, Arg, His, Phe, or Tyr

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 14
Xaa Xaa Phe Arg Xaa Xaa Xaa Trp
1 5

<210> 15
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> SITE
<222> (1)
<223> Xaa is independently selected from the group Gly, Ala, Ile, Leu, Val, Ser, and Thr

<220>
<221> SITE
<222> (2)
<223> Xaa is independently selected from the group Gly, Ala, Ile, Leu, Val, Ser, and Thr

<220>
<221> SITE
<222> (5)
<223> Xaa is independently selected from the group Gly, Ala, Ile, Leu, Val, Ser, and Thr

<220>
<221> SITE
<222> (6)
<223> Xaa is independently selected from the group Gly, Ala, Ile, Leu, Val, Ser, and Thr

<220>
<221> SITE
<222> (7)
<223> Xaa is independently selected from the group Gly, Ala, Ile, Leu, Val, Ser, and Thr

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 15
Xaa Xaa Phe Arg Xaa Xaa Xaa Trp
1 5

<210> 16
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Oligonucleotide probe

<400> 16
cgacgcgctt ggcgggagat agaaaagtgc 30

<210> 17
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Oligonucleotide probe

<400> 17
atttttctga tttggttaa 19

<210> 18
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Oligonucleotide probe

<400> 18
atggggcgga ga 12

<210> 19
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide probe

<400> 19
cgccttgaat gacgtcaagg ccgcga 26

<210> 20
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 20
Ala Val Arg Trp His Phe
1 5

<210> 21
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 21
Trp Ala Arg Trp His Phe
1 5

<210> 22
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 22
Trp Val Ala Trp His Phe
1 5

<210> 23
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 23
Trp Val Arg Ala His Phe
1 5

<210> 24
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 24
Trp Val Arg Trp Ala Phe
1 5

<210> 25
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 25
Trp Val Arg Trp His Ala
1 5

<210> 26
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 26
Gly Ser Arg Ile Leu Thr Phe Arg Ser
1 5

<210> 27
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 27
Ile Leu Thr Phe Arg Ser Gly Ser Trp
1 5

<210> 28
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 28
Phe Arg Gly Ser Trp Ala Ser
1 5

<210> 29
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 29
Leu Thr Phe Arg Ser Gly Ser Trp Tyr Ala Ser
1 5 10

<210> 30
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 30
Arg Ile Leu Thr Phe Arg Ser Gly Ser Trp Tyr Ala Ser
1 5 10

<210> 31
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 31
Arg Ile Leu Thr Phe Arg Ser Gly Ser
1 5

<210> 32
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 32
Arg Ile Leu Thr Phe Arg Ser Gly Ser Trp Tyr
1 5 10

<210> 33
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 33
Ser Arg Ile Leu Thr Phe Arg Ser Gly Ser Trp Tyr
1 5 10

<210> 34
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 34
Gly Ser Ala Ile Leu Thr Phe Arg Ser Gly Ser Trp Tyr Ala Ser
1 5 10 15

<210> 35
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 35
Gly Ser Arg Ile Leu Thr Ala Arg Ser Gly Ser Trp Tyr Ala Ser
1 5 10 15

<210> 36
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 36
Gly Ser Arg Ile Leu Thr Phe Ala Ser Gly Ser Trp Tyr Ala Ser
1 5 10 15

<210> 37
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 37
Gly Ser Arg Ile Leu Thr Phe Arg Ser Gly Ser Ala Tyr Ala Ser
1 5 10 15

<210> 38
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 38
Gly Ser Arg Ile Leu Thr Phe Arg Ser Gly Ser Trp Ala Ala Ser
1 5 10 15

<210> 39
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 39
Ala Val Arg Ala His Phe
1 5

<210> 40
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 40
Gly Ser Arg Ile Leu Thr Ala Arg Ser Gly Ser Ala Tyr Ala Ser
1 5 10 15